ERIS Lifesciences Ltd - ERIS LIFESCIENCE Share Price

Sector: Pharmaceuticals | ISIN: INE406M01024
₹ 876.30 (3.08%) icon29 Sep, 2023, 3:58:30 PM

ERIS Lifesciences Ltd Stock View

info icon
Edit Image
STRONG BUY
Target | 25 Sep, 2023 912.455 (4.13%)

Eris Lifesciences Limited is an India-based company that is primarily engaged in the manufacturing and marketing of pharmaceutical products. The Company’s manufacturing plant is located in G... Read More

ERIS Lifesciences Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 9/29/2023 3:58:30 PM

    ₹ 876.3 26.15 3.08
  • Open
  • ₹ 856.15
  • Prev. Close
  • ₹ 850.15
  • Turnover(Lac.)
  • ₹ 25,274
  • Day's High
  • ₹ 927.95
  • Day's Low
  • ₹ 855
  • 52 Week's High
  • ₹ 927.95
  • 52 Week's Low
  • ₹ 551.3
  • Book Value
  • ₹ 171.49
  • Face Value
  • ₹ 1
  • Mkt Cap (₹ Cr.)
  • 11,919.72
  • P/E
  • 28.88
  • EPS
  • 30.37
  • Divi. Yield
  • 0.84

ERIS Lifesciences Ltd Corporate Actions

07 Aug , 2023

12:00 AM

AGM

Announcement date: 07 Aug , 2023

View Details

31 Jul , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

31 Jul , 2023

12:00 AM

10 May , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

10 Jan , 2023

12:00 AM

10 Jan , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

11 Oct , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

11 Oct , 2022

12:00 AM

02 Sep , 2023

12:00 AM

BookCloser

View Details

ERIS Lifesciences Ltd News and Update

Image not found
  • 27 September, 2023 |
  • 8:33 PM

A 51% stake in TCNS Clothing has been acquired by Aditya Birla Fashion Retail Ltd (ABFRL), making it a promoter of the women's clothing company.

Image not found
  • IIFL News Service |
  • 26 September, 2023 |
  • 8:31 PM
Image not found
Article Image
  • IIFL News Service |
  • 22 September, 2023 |
  • 8:26 PM

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

ERIS Lifesciences Ltd SHAREHOLDING SNAPSHOT
02 October , 2023 | 08:21 PM

PROMOTER - TOTAL52.86%

Indian: 52.86%

Foreign: 0%

NON-PROMOTER - TOTAL 47.14%

Institutions: 24.51%

Non-Institutions: 22.63%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details
ad IconAd Image

ERIS Lifesciences Ltd FINANCIALS

ERIS Lifesciences Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT ERIS Lifesciences Ltd

  • Management Info Not Found
  • Summary

    Eris Lifesciences Limited was incorporated on January 25, 2007. Subsequently, the name of the company was changed to Eris Lifesciences Private Limited on February 9, 2007. Further, the Company was converted into a Public Limited cCompany and the name was changed to Eris Lifesciences Limited on February 2, 2017. The Company has a manufacturing plant in Guwahati, Assam and is presently engaged in manufacturing and marketing of pharmaceutical products. It has presence in high growth chronic, sub chronic and acute therapeutic areas that require high intervention of specialist and super specialist doctors. Apart from this, it has a portfolio of 112 Mother Brands across therapy areas. The company develops, manufactures and commercializes branded pharmaceutical products in selected therapeutic areas within the chronic and acute categories of the Indian Pharmaceutical Market (IPM), such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infective. Its focus has been on developing products in the chronic and acute categories which are linked to lifestyle related disorders. Its operations are supported by a distribution network of 22 Sales depots, 2,059 Stockists and more than 5,00,000 retail chemists.In 2007, the company launched Eris division focused on cardiology and diabetes segment. In 2008, the company launched Nikkos division focused on gastroenterology and orthopedics segment. In 2009, the company launched Adura division focused on cardiology and diabetes... Read More


    Reports by ERIS Lifesciences Ltd


    Reports by ERIS Lifesciences Ltd

    Company FAQ

    No Record Found